Advances in Drug Discovery from Hit to Candidate Webinar

Join us at this virtual conference to learn about new insights and advances that are accelerating drug discovery—from hit to candidate—for small molecules and biologics. Promising hits often have development challenges that require innovative solutions to reach the key milestone of declaring a candidate.

The live webinar format will have one speaker per week, followed by an interactive Q&A session with a global audience.

REGISTER NOW

Upcoming Events

January 20th

9:00am PDT

Dr. Haizhen Liu,

Assistant Director of R&D at BioAtla
Novel Conditional Active Bispecific T Cell Engagers Targeting Solid Tumors

February 10th

9:00am PDT

Dr. Vincent Jacques,

Sr VP of Research and Early Development
Deuterium in drug discovery and development

FULL AGENDA

REGISTER NOW

Next Gen Computational & AI Approaches	Small Molecules, Big Advances: Early to Late Lead Op	Modern Biologics: Antibodies & Cell Therapies	Advanced Preclinical & Translational Animal Models
Modeling approaches and in silico systems used to shorten discovery timelines and reduce cost	Modern technologies and synthetic methodologies to accelerate the H2L and LO phases of drug discovery	Includes the growing impact of biologics, current challenges and innovative technologies	Innovative approaches to better assess PK, efficacy and safety closer to clinical settings
Dr. Apurba K Bhattacharjee, Georgetown University Medical Center, Georgetown University(More Info) Pharmacophore modeling for potential drug discovery – October 14th, 2020 View recording Q&A Dr. Evan Feinberg, Genesis Therapeutics(More Info) Unifying AI and biotech to accelerate and optimize drug discovery & development – November 11th, 2020 Dr. Zachary Sun, Tierra Biosciences(More Info) Cell-free synthetic biology for high-throughput, custom protein production -December 16th, 2020 Victor Antontsev, VeriSIM Life(More Info) BIOiSIM: Next Generation Hybrid Modeling for Preclinical and Clinical Drug Development – TBD Dr. Ana Cristina Puhl Rubio, Collaborations Pharmaceuticals(More Info) COVID-19 Drug Discovery at Collaborations Pharmaceuticals – March 3rd, 2021	Dr. Spandan Chennamadhavuni, Emory University(More Info) Novel Macrocyclic Drugs for cancer Treatment – Exploring “beyond rule-of-five (bRo5)” chemical space – October 21st, 2020 View recording Q&A Dr. Justin Hall, Pfizer Pharmaceuticals(More Info) A simple model for determining ligand affinity from irreversible thermal shifts – October 28st, 2020 View recording Dr. Lewis D. Pennington, Alkermes(More Info) Leveraging the Necessary Nitrogen Atom for Multiparameter Optimization in Chemical Biology and Drug Discovery – Nov 18^th, 2020 View recording Dr. Surya K. De, Supra Sciences(More Info) Drug Discovery Hit to Lead – Inhibitors of PI-3K/AKT/mTOR Pathway – January 13th, 2021 View recording Dr. Vincent Jacques, DeuteRx, LLC(More Info) Deuterium in drug discovery and development – February 10th, 2021 Dr. Brian Sparling, Accent Therapeutics(More Info) RNA-Modifying Enzyme Inhibitors as Precision Cancer Therapeutics – March 10th, 2021 Dr. Corey R. Hopkins, University of Nebraska Medical Center(More Info) Discovery of novel PDE4B inhibitors as in vivo tool compounds for cocaine use disorder – March 24^th, 2021 Dr. Michael Petrassi, California Institute of Biomedical Research(More Info) Translating Innovative Academic Research into Drug Discovery Programs and INDs using Industrial Practices and Standards – April 7^th, 2021 Dr. Apurba Dutta, University of Kansas(More Info) Cytotoxic Marine Natural Product Jaspine B: A Medicinal Chemical Investigation – April 14th, 2021 Dr. Nicholas A. Meanwell, Bristol Myers Squibb(More Info) The Discovery of the HIV-1 Attachment Inhibitor Fostemsavir – April 28^th, 2021 Dr. Bing Xia, GlaxoSmithKline(More Info) DEL-Enabled Discovery of Novel MoA and Structurally Unique IDO1 Inhibitors – TBD Dr. Ian Storer, AstraZeneca(More Info) Fragment screening as an adaptable approach for hit-to-lead generation in medicinal chemistry – May 5^th, 2021	Dr. Lore Gruenbaum, The Leukemia & Lymphoma Society (More Info) Antibody and Cell Therapies in blood cancer: successes & challenges – December 2nd, 2020 View recording Dr. Haizhen Liu, BioAtla(More Info) Novel Conditional Active Bispecific T Cell Engagers Targeting Solid Tumors – January 20th, 2021 Dr. Sreerupa Challa, Cugene(More Info) Role of Bi-specific antibodies in next generation anti-tumor Immunotherapies – February 17th, 2021 Dr. Uriel Moreno, Stanford University(More Info) Plasticity of Human Natural Killer Cells in the Tumor Microenvironment -March 17th, 2021	Dr. Yurong Lai , Gilead Sciences(More Info) Model informed compound selection in drug discovery: The Why and How – November 4th, 2020 View recording Q&A Dr. Kin-Hoe Chow, Dana Farber Institute(More Info) Creation of patient derived cancer models at scale leverages patient diversity for improved clinical trials predictions – December 9th, 2020

Next Gen Computational & AI Approaches

Small Molecules, Big Advances: Early to Late Lead Op

Modern Biologics: Antibodies & Cell Therapies

Advanced Preclinical & Translational Animal Models

Modeling approaches and in silico systems used to shorten discovery timelines and reduce cost

Modern technologies and synthetic methodologies to accelerate the H2L and LO phases of drug discovery

Includes the growing impact of biologics, current challenges and innovative technologies

Innovative approaches to better assess PK, efficacy and safety closer to clinical settings

Dr. Apurba K Bhattacharjee, Georgetown University Medical Center, Georgetown University(More Info)
Pharmacophore modeling for potential drug discovery – October 14th, 2020
View recording
Q&A

Dr. Evan Feinberg, Genesis Therapeutics(More Info)
Unifying AI and biotech to accelerate and optimize drug discovery & development – November 11th, 2020

Dr. Zachary Sun, Tierra Biosciences(More Info)
Cell-free synthetic biology for high-throughput, custom protein production -December 16th, 2020

Victor Antontsev, VeriSIM Life(More Info)
BIOiSIM: Next Generation Hybrid Modeling for Preclinical and Clinical Drug Development – TBD

Dr. Ana Cristina Puhl Rubio, Collaborations Pharmaceuticals(More Info)
COVID-19 Drug Discovery at Collaborations Pharmaceuticals – March 3rd, 2021

Dr. Spandan Chennamadhavuni, Emory University(More Info)
Novel Macrocyclic Drugs for cancer Treatment – Exploring “beyond rule-of-five (bRo5)” chemical space – October 21st, 2020
View recording
Q&A

Dr. Justin Hall, Pfizer Pharmaceuticals(More Info)
A simple model for determining ligand affinity from irreversible thermal shifts – October 28st, 2020
View recording

Dr. Lewis D. Pennington, Alkermes(More Info)
Leveraging the Necessary Nitrogen Atom for Multiparameter Optimization in Chemical Biology and Drug Discovery – Nov 18^th, 2020
View recording

Dr. Surya K. De, Supra Sciences(More Info)
Drug Discovery Hit to Lead – Inhibitors of PI-3K/AKT/mTOR Pathway – January 13th, 2021
View recording

Dr. Vincent Jacques, DeuteRx, LLC(More Info)
Deuterium in drug discovery and development – February 10th, 2021

Dr. Brian Sparling, Accent Therapeutics(More Info)
RNA-Modifying Enzyme Inhibitors as Precision Cancer Therapeutics – March 10th, 2021

Dr. Corey R. Hopkins, University of Nebraska Medical Center(More Info)
Discovery of novel PDE4B inhibitors as in vivo tool compounds for cocaine use disorder – March 24^th, 2021

Dr. Michael Petrassi, California Institute of Biomedical Research(More Info)
Translating Innovative Academic Research into Drug Discovery Programs and INDs using Industrial Practices and Standards – April 7^th, 2021

Dr. Apurba Dutta, University of Kansas(More Info)
Cytotoxic Marine Natural Product Jaspine B: A Medicinal Chemical Investigation – April 14th, 2021

Dr. Nicholas A. Meanwell, Bristol Myers Squibb(More Info)
The Discovery of the HIV-1 Attachment Inhibitor Fostemsavir – April 28^th, 2021

Dr. Bing Xia, GlaxoSmithKline(More Info)
DEL-Enabled Discovery of Novel MoA and Structurally Unique IDO1 Inhibitors – TBD

Dr. Ian Storer, AstraZeneca(More Info)
Fragment screening as an adaptable approach for hit-to-lead generation in medicinal chemistry – May 5^th, 2021

Dr. Lore Gruenbaum, The Leukemia & Lymphoma Society (More Info)
Antibody and Cell Therapies in blood cancer: successes & challenges – December 2nd, 2020
View recording

Dr. Haizhen Liu, BioAtla(More Info)
Novel Conditional Active Bispecific T Cell Engagers Targeting Solid Tumors – January 20th, 2021

Dr. Sreerupa Challa, Cugene(More Info)
Role of Bi-specific antibodies in next generation anti-tumor Immunotherapies – February 17th, 2021

Dr. Uriel Moreno, Stanford University(More Info)
Plasticity of Human Natural Killer Cells in the Tumor Microenvironment -March 17th, 2021

Dr. Yurong Lai , Gilead Sciences(More Info)
Model informed compound selection in drug discovery: The Why and How – November 4th, 2020
View recording
Q&A

Dr. Kin-Hoe Chow, Dana Farber Institute(More Info)
Creation of patient derived cancer models at scale leverages patient diversity for improved clinical trials predictions – December 9th, 2020

Accelerated Development: Fast path to the clinic	Discovery & preclinical approaches that enable rapid development	Dr. Daniel Treffer, Melt Prep (More Info) Rapid and lossless prototyping of HME formulations in the milligram to gram scale via Vacuum Compression Molding – June 30th View recording Q&A Dr. Chad Brown, Merck (More Info) Hot Melt Extrusion as a Key Enabler of Developing Products of Low Solubility Compounds – June 2nd Q&A Dr. Xiaohu Deng, Viracta (More Info) Phase-appropriate CMC Strategies in Drug Product Development – July 14th View recording Q&A Chandra Kelley, Pfanstiehl (More Info) Key Considerations in Accelerating Biopharma Formulation Development – August 11th Seth Forster, Merck (More Info) Long-Acting Implants: Design for Durable Drug Delivery – August 4th Dr. John Shelley, Schrodinger (More Info) Formulation Development for Small Molecules and Biologics Enhancements with Molecular Modeling – July 28th View recording Dr. Andrea Browning, Schrodinger (More Info) Formulation Development for Small Molecules and Biologics Enhancements with Molecular Modeling – July 28th View recording Dr. Raimar Löbenberg, University of Alberta (More Info) Presentation title coming soon – Date TBD
Enhanced Bioavailability	Approaches that enhance solubility of challenging API to enable clinically viable formulations	Dr. Harsh Chauhan, Creighton University (More Info) Formulation Considerations for development of Ternary Solid Dispersions – June 23rd View recording Dr. Dedong Wu, Astrazeneca (More Info) Improving Bioavailability by Prodrug Approach – September 1st Dr. Feng Zhang, UT Austin (More Info) Hot-melt extrusion to prepare amorphous solid dispersions: key concepts and common misperceptions – July 7th View recording Q&A Dr. Mo Maniruzzaman, UT Austin (More Info) 3D printing and state-of-the-art manufacturing techniques to advance drug delivery – Date TBD Dr. Yi-Ling Hsieh, AbbVie (More Info) Lipid-Based Formulation – The Impact on Biopharmaceutics and Patient Centricity – July 21st View recording Dr. Abu Serajuddin, St. John’s University (More Info) Development of HPMCAS-based amorphous solid dispersions by melt extrusion 21st – Date TBD
Continuous Processing	Topics covered will include uses of technologies such as: amorphous solid dispersion, continuous granulation, coating and extrusion	Dr. Michael Thompson, McMaster University (More Info) Developments in Twin-Screw Granulation – May 26th View recording Q&A Andy Birkmire, GEA (More Info) Successful Strategies for Developing a Continuous Manufacturing Process – June 9thView recording Q&A Jim Marjeram, O’Hara (More Info) Advantages of Continuous Tablet Coating – September 8th
Oral Delivery	Innovative approaches to address oral delivery of biologics, including: proteins, peptides, nucleic acids, and beyond	Dr. John Vrettos, Enteris BioPharma (More Info) Breaking Through the Barriers of Oral Biologics – June 16thView recording Q&A Dr. Stephen Hoag, University of Maryland (More Info) Presentation title coming soon – Date TBD

REGISTER NOW